Recent Study: Second Cancers Deadlier for Younger People

(HealthDay News) When a second cancer strikes, it tends to be far more deadly in the young, a new study reveals.

The findings may help explain the poor outcomes of younger cancer patients overall, the researchers added.

The researchers also found that survival odds for nearly all types of cancer are better for an initial cancer than for a second, unrelated cancer. That difference is greatest among patients younger than 40, the study authors said.

"Although the increased incidence of second cancers is well known among cancer survivors, less is known about outcomes of these cancers or the influence of age," said study author Theresa Keegan.

Keegan is a cancer epidemiologist at the University of California, Davis Comprehensive Cancer Center.

The researchers analyzed 1992-2008 data on more than 1 million cancer patients of all ages in the United States. They then looked for second cancers, meaning a new cancer, not a recurrence.

They found that the five-year survival rate for children and young adults was 80 percent after a first cancer. However, it dropped to 47 percent for children and 60 percent for young adults in cases of second cancers, Keegan and her colleagues said in a university news release.


Meanwhile, survival rates in older adults were 70 percent and 61 percent, respectively.

When the researchers focused on the 14 most common cancer types that affect young adults, they found that for all but two, there were significant survival differences depending on whether it was a first or second cancer.

For example, the five-year survival rate for young adults with acute myeloid leukemia was 57 percent if it was a first cancer, but only 29 percent if it was a second cancer. The five-year survival rate for young adult women with breast cancer was 81 percent if it was a first cancer but only 63 percent if it was a second cancer.

It's not clear why younger patients tend to do worse than older patients with the same second cancers.

But the researchers suggested several possible reasons, including worse response to treatment, limitations on the types or doses of treatments that they can receive as a result of prior cancer treatment, or reduced physical reserves that lower their ability to tolerate treatment.

HealthDay Reporter By Robert Preidt

Source: webmd.com